Open AccessThe Role of Radium 223 Planar Whole-Body Scan in the Management of Patients with Bone Metastates
Publication year - 2019
Publication title -
advances in bioengineering and biomedical science research
Language(s) - English
Resource type - Journals
ISSN - 2640-4133
DOI - 10.33140/abbsr.02.04.01
Subject(s) - medicine , prostate cancer , radium 223 , multidisciplinary approach , disease , radiation oncologist , cancer , radium , oncology , medical physics , radiation therapy , bone metastasis , social science , sociology , physics , nuclear physics
The multidisciplinary treatment with targeted alpha therapy, as the treatment with Radium 223, plays an important role in themanagement of patients with castration resistance prostate cancer and metastatic bone disease. The AUA approved the Ra223as the second line of treatment of castration resistance prostate cancer in patients with bone metastases, in the absence ofvisceral metastases. Currently the EMA authorizes the use of Ra223 at a dose of 55 kBq / kg for a total of 6 administrationsin patients with CRPC, but the dose of Ra223 needs to be made on an individual patient basis taking into consideration thepotential clinical benefits and risk.We have outlined a new methodology, which can be executed in all departments of nuclear medicine in collaboration withhealth-related physics at no cost. Our methodology allows a correct evaluation of the doses of Radium 223 to be administeredand of the number of cycles to be performed, to increase the therapeutic efficacy.We can avoid overtreatment or undertreatment of patients ensuring a perfect fit between patients and Ra223 treatment. Themultidisciplinary approach between nuclear physician, oncologist and health related physics is crucial throughout the treatmentprocess to improve QoL in patients at risk.